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Abstract 23 
CRISPR-Cas systems are bacterial adaptive immune pathways that have revolutionized biotechnology 24 
and biomedical applications. Despite the potential for human therapeutic development, there are many 25 
hurdles that must be overcome before its use in clinical settings. Some clinical safety concerns arise from 26 
persistent activity of Cas9 after the desired editing is complete, or from editing activity in unintended cell 27 
types or tissues upon in vivo delivery [e.g. by adeno-associated viruses (AAV)]. Although tissue-specific 28 
promoters and serotypes with tissue tropisms can be used, suitably compact promoters are not always 29 
available for desired cell types, and AAV tissue tropisms are not absolute. To reinforce tissue-specific 30 
editing, we exploited anti-CRISPR proteins (Acrs), which are proteins evolved as countermeasures against 31 
CRISPR immunity. To inhibit Cas9 in all ancillary tissues without compromising editing in the target 32 
tissue, we established a flexible platform in which an Acr transgene is repressed by endogenous, tissue-33 
specific microRNAs (miRNAs). We demonstrate that miRNAs regulate the expression of an Acr transgene 34 
bearing miRNA-binding sites in its 3’ UTR, and control subsequent genome editing outcomes in a cell-35 
type specific manner. We also show that the strategy is applicable to multiple Cas9 orthologs and their 36 
respective Acrs. Furthermore, we demonstrate that in vivo delivery of Cas9 and Acrs that are targeted for 37 
repression by liver-specific miR-122 allow editing in the liver while Acrs devoid of miRNA regulation 38 
prevent Cas9 activity. This strategy provides additional safeguards against off-tissue genome editing by 39 
confining Cas9 activity to selected cell types. 40 
 41 
Introduction 42 
Clustered, regularly interspaced, short, palindromic repeats (CRISPR) and CRISPR-associated (cas) genes 43 
comprise prokaryotic adaptive immune defense systems that are classified into two major classes and 44 
multiple types and subtypes (e.g. II-A, -B, and -C) (Makarova et al. 2018). Cas9s are monomeric effector 45 
proteins in type II systems that can target nearly any DNA sequence when guided by a CRISPR RNA 46 
(crRNA) base paired with a trans-activating RNA (tracrRNA), or as a fused form of both RNAs known as 47 
single guide RNA (sgRNA) (Deltcheva et al. 2011; Garneau et al. 2010; Jinek et al. 2012). The robustness 48 
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and ease of Cas9 programmability have greatly facilitated its rapid adoption in genome editing and 49 
modulation (Komor et al. 2017). As medical, agricultural, and environmental technologies advance, safety 50 
concerns must be considered and addressed, especially with potential human therapeutics. In vivo 51 
therapeutics will often require not only precise editing at the intended genomic site but also in the 52 
intended tissue, given the possible risks of unwanted double-strand break (DSB) induction. For example, 53 
Cas9-induced DSBs can elicit translocations that can be associated with heritable disorders or various 54 
kinds of cancer, or large deletions and other rearrangements (Jiang et al. 2016; Maddalo et al. 2014; 55 
Kosicki et al. 2018). Moreover, some delivery modalities such as viral vectors are likely to affect many cell 56 
types and tissues beyond the intended therapeutic target (Hinderer et al. 2018). AAV is currently the most 57 
widely used transgene delivery vector for therapeutic applications in preclinical and clinical settings. 58 
Different AAV serotypes have some tissue tropism, however, they can still infect broad ranges of tissues in 59 
vivo (Gao et al. 2004). Although tissue-specific promoters can be used to drive transgene expression in 60 
particular cell types (Walther and Stein 1996), some target tissues lack promoters that are sufficiently 61 
active, specific, or small for AAV deployment. These limitations necessitate the development of new 62 
regulatory strategies to enforce tissue specificity for in vivo applications. 63 
 64 
Although several means of regulating genome editing activities have been reported, a prominent recent 65 
advance has resulted from the discovery of anti-CRISPR (Acr) proteins (Bondy-Denomy et al. 2013). Acrs 66 
are small proteins encoded by bacteriophages and other mobile genetic elements that have evolved as 67 
natural countermeasures against CRISPR-Cas immunity. Type II Acrs targeting Cas9 orthologs (Pawluk 68 
et al. 2016; Rauch et al. 2017; Hynes et al. 2017, 2018), as well as the recently-discovered type V Acrs 69 
targeting Cas12a (Watters et al. 2018; Marino et al. 2018), are of particular interest because they can 70 
potentially provide temporal, spatial, or conditional control over established genome editing systems. 71 
Applications of Acrs have been demonstrated in bacteria (Marshall et al. 2018; Rauch et al. 2017), in 72 
yeasts to inhibit gene drives (Goeckel et al. 2019), and in mammalian cells to modulate genome editing, 73 
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dCas9-based imaging, epigenetic modification, and genetic circuits (Pawluk et al. 2016; Rauch et al. 2017; 74 
Shin et al. 2017; Bubeck et al. 2018; Liu et al. 2018; Nakamura et al. 2019). 75 
 76 
To improve current technologies that regulate the tissue specificity of editing, we have developed an Acr-77 
based approach to inhibit Cas9 in all ancillary tissues while allowing editing in the target tissue. To 78 
spatially regulate Acr expression, we exploited endogenous tissue-specific microRNAs (miRNAs) to 79 
repress Acr expression in the target tissue. MiRNAs are a class of small regulatory RNAs whose 80 
mechanisms of messenger RNA (mRNA) regulation are extensively studied (Jonas and Izaurralde 2015). 81 
These RNAs load into an argonaute protein (e.g. Ago2) to form RNA-induced silencing complexes 82 
(RISCs) that recognize complementary sequences present in mRNA targets, leading to translational 83 
repression and mRNA destabilization (Bartel 2018). In mammalian cells, Ago2-loaded miRNAs can 84 
subject extensively or perfectly complementary mRNA targets to endonucleolytic cleavage, enabling 85 
strong downregulation. Since miRNA response elements (MREs) are very small (~22 nucleotides or less), 86 
this regulatory modality places minimal burden on AAV vector capacity, which is limited to ~4.8 kb. 87 
Moreover, large numbers of mammalian cell and tissue types express specific combinations of tissue-88 
restricted miRNAs (Lagos-Quintana et al. 2002).  89 
 90 
Here we establish a flexible platform in which an Acr transgene is repressed by endogenous, tissue-specific 91 
miRNAs to control Acr expression spatially. We demonstrate that miRNAs can regulate the expression of 92 
an Acr transgene bearing miRNA-binding sites in its 3’ untranslated region (UTR) and control subsequent 93 
genome editing outcomes in a cell-type specific manner. We also show that the strategy is applicable to 94 
multiple Cas9 orthologs and their respective Acrs, including the widely-used Streptococcus pyogenes (SpyCas9) 95 
(Cong et al. 2013; Mali et al. 2013; Jinek et al. 2013; Cho et al. 2013; Hwang et al. 2013) as well as the 96 
more readily AAV-deliverable Cas9 orthologs from Neisseria meningitidis (Nme1Cas9 and Nme2Cas9) 97 
(Ibraheim et al. 2018; Edraki et al. 2018). Furthermore, we have expressed anti-CRISPR proteins in mice 98 
to achieve efficient inhibition of Cas9-mediated genome editing in vivo without detectable toxicity. We 99 
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show that co-delivery of Cas9, guide RNA, and miR-122-repressible Acr transgenes allow editing in the 100 
liver (the only tissue where miR-122 is expressed), while an otherwise identical Acr transgene that lacks 101 
any miR-122 MREs effectively prevent Cas9 activity. This strategy establishes the in vivo efficacy of Acrs 102 
in mammals and provides the basis for restriction of undesired off-tissue editing by confining Cas9 activity 103 
to selected cell types. 104 
 105 
Results 106 
 107 
AAV delivery of all-in-one Nme1Cas9/sgRNA results in editing in various tissues 108 
Previously, our group has used all-in-one AAV8 to deliver a human-codon-optimized Nme1Cas9 for 109 
genome editing in vivo (Ibraheim et al. 2018). Nme1Cas9 is smaller and less prone to off-target editing 110 
than the widely used SpyCas9 (Amrani et al. 2018). Upon delivery of all-in-one rAAV8 viruses expressing 111 
hNme1Cas9 driven by a ubiquitous U1a promoter and sgRNA via tail vein injection, we observed high 112 
editing efficiency in liver tissues collected 50 days post-injection (Ibraheim et al. 2018). To gauge editing 113 
efficiencies in non-target tissues outside of the liver, tissues from cardiac and skeletal muscle 114 
(gastrocnemius muscle) as well as kidney and brain were collected and analyzed (Supplemental Fig. 1). 115 
Although lower than the editing observed in liver tissues (51.33±4.93 %), appreciable indel frequencies 116 
were observed in different organs, especially in the heart (22.33±3.79 %) (Supplemental Fig. 1). This is 117 
consistent with previous reports that AAV8 effectively transduces mouse hepatocytes but also infects 118 
skeletal and cardiac muscles (Nakai et al. 2005) as well as brain at high doses (Zincarelli et al. 2008). 119 
These observations, along with the known multi-tissue tropisms of other AAV serotypes (Zincarelli et al. 120 
2008), underscore the potential benefit of using miRNA-repressible Acr transgenes to reinforce tissue-121 
specific editing. 122 
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A strategy for microRNA-regulated anti-CRISPR proteins 124 
Endogenous miRNA-mediated post-transcriptional gene silencing has proven to be an effective and 125 
tissue-specific approach to regulate transgene expression upon AAV delivery in vivo (Xie et al. 2011). 126 
Delivery of Cas9/sgRNA via AAV has the potential to induce editing in multiple transduced tissues (e.g. 127 
heart, skeletal muscles etc.); however, co-delivery of the miRNA-repressible Acr will inhibit editing in such 128 
non-target tissues due to the latter’s lack of tissue-specific miRNAs (and therefore their inability to silence 129 
the expression of the Acr inhibitor). In the case of the liver-specific miRNA miR-122, in the target tissue 130 
the Acr gene with miR-122 MREs will be repressed, enabling Cas9-mediated editing (Fig. 1A). In contrast, 131 
off-tissue editing (e.g. in cardiac and skeletal muscle, Supplemental Fig. 1) will be inhibited by the Acr, 132 
since those extrahepatic tissues lack miR-122 and therefore fail to silence Acr expression. To validate this 133 
concept, we chose two well-established Cas9-Acr combinations: AcrIIC3Nme and Nme1Cas9/Nme2Cas9 134 
(Type II-C; (Pawluk et al. 2016; Edraki et al. 2018)) as well as AcrIIA4Lmo and SpyCas9 (Type II-A; 135 
(Rauch et al. 2017)). Nme2Cas9 is a recently reported Cas9 ortholog that has a dinucleotide (N4CC) 136 
protospacer adjacent motif (PAM) (Edraki et al. 2018), enabling a target site density comparable to that of 137 
SpyCas9 (NGG PAM). A type II-C Nme1Cas9/Nme2Cas9 inhibitor, AcrIIC3Nme, limits target DNA 138 
affinity (Harrington et al. 2017; Zhu et al. 2019). AcrIIA4Lmo inhibits the widely-used SpyCas9 and also 139 
prevents DNA binding, in this case by occluding the PAM-binding cleft (Rauch et al. 2017; Dong et al. 140 
2017; Shin et al. 2017; Yang and Patel 2017). For our in vitro validations, both Cas9 and Acr expression 141 
vectors were driven by the cytomegalovirus (CMV) promoter. We generated codon-optimized Acr 142 
expression vectors identical in every respect except for the presence or absence of MREs in the 3’ UTR 143 
(Supplemental Table 1). Since miR-122 is a well-validated miRNA that is highly expressed specifically in 144 
hepatic cells, we decided to validate the concept using this miRNA. We placed three tandem miR-122 145 
binding sites (3xmiR122BS) in the 3’ UTR of each Acr gene, which also included a C-terminal mCherry 146 
fusion to enable expression to be detected by fluorescence microscopy or flow cytometry (Fig. 1B). Fusion 147 
of heterologous domains do not compromise the inhibitory potency of these Acrs (Goeckel et al. 2019; 148 
Nakamura et al. 2019). 149 
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  150 
Validation of microRNA-repressible anti-CRISPR expression vectors 151 
We used a human hepatocellular carcinoma cell line (Huh-7) that abundantly expresses miR-122, in 152 
contrast to non-hepatic cell lines such as human embryonic kidney (HEK293T) cells (Fukuhara et al. 153 
2012). As an initial test of miR-122 repression of Acr expression, we transfected cells with plasmids 154 
expressing AcrIIC3-FLAG-mCherry-3xmiR122BS, AcrIIA4-FLAG-mCherry-3xmiR122BS, or their 155 
respective control vectors lacking the miR-122 binding sites (Fig. 1B). A separate GFP expression plasmid 156 
was also included to indicate transfection efficiencies in each cell line. When these vectors were transiently 157 
transfected, the expression of mCherry-fused Acr with miR-122 MREs was dramatically suppressed in 158 
Huh7 cells whereas Acr-mCherry lacking 3xmiR122BS was still well expressed (Fig. 2A). In HEK293T 159 
cells, there was no discernible difference in mCherry signal from the Acr and Acr-3xmiR122BS constructs 160 
based on both fluorescence microscopy and flow cytometry (Fig. 2B). Acr expression was also confirmed 161 
by anti-FLAG western blot analysis (Fig. 2). Compared to HEK293T cells, transfection efficiency was 162 
lower in Huh-7 cells as indicated by a decrease in overall GFP and mCherry signals (Fig. 2A). 163 
Nevertheless, fluorescence microscopy, flow cytometry, and Western blot analysis consistently revealed 164 
effective reductions of both AcrIIC3-3xmiR122BS and AcrIIA4-3xmiR122BS expression in Huh-7, but 165 
not in HEK293T cells. Expression of Acrs lacking miR-122 MREs was unaffected in both cell lines, 166 
consistent with effective regulation of Acr by miR-122 only in hepatic cells. 167 
  168 
MicroRNA repression enables escape from anti-CRISPR inhibition during genome editing 169 
in hepatocytes 170 
Having demonstrated that anti-CRISPR repression in hepatocyte-derived cells can be conferred by miR-171 
122 MREs, we then tested whether this repression is sufficient to allow genome editing by Cas9 orthologs 172 
(SpyCas9, Nme1Cas9 and Nme2Cas9). We transiently transfected separate expression plasmids for Cas9, 173 
a cognate sgRNA, and an Acr, with the latter construct either including or omitting miR-122 binding 174 
sites. We chose validated, endogenous sites in the human genome for each Cas9 ortholog (Fig. 3): the 175 
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Nme1Cas9 target site NTS33 in the VEGFA gene (Fig. 3A), the Nme2Cas9 target site TS6 in the 176 
LINC01588 gene (Fig. 3B), and the SpyCas9 target site 1617 in the BCL11A enhancer (Fig. 3C) (Amrani et 177 
al. 2018; Edraki et al. 2018; Wu et al. 2019). In HEK293T cells, AcrIIC3Nme and AcrIIA4Lmo robustly 178 
inhibited genome editing by Nme1/2Cas9 and SpyCas9, respectively, as expected (Pawluk et al. 2016; 179 
Rauch et al. 2017) (Fig. 3). The presence or absence of miR-122 MREs had no significant effect on 180 
editing inhibition in this non-miR-122-expressing cell type. Although the editing efficiency was variable 181 
among Cas9 orthologs at these target sites, and although transfection efficiencies were reduced in Huh-7 182 
cells, AcrIIC3Nme and AcrIIA4Lmo  also prevented editing in this cell type when expressed from constructs 183 
that lack miR-122 MREs. By contrast, Acrs plasmids that incorporated miR-122 MREs in the 3’UTRs 184 
failed to inhibit Cas9 editing in Huh-7 cells, as indicated by editing efficiencies that were similar to the no-185 
Acr control (Fig. 3). This trend was true for all three Cas9 orthologs tested. 186 
  187 
MiR-122-dependent in vivo genome editing conferred by an anti-CRISPR protein  188 
For our in vivo tests we focused on Nme2Cas9, due to its compact size, high target site density, and relative 189 
lack of off-target editing, all of which are advantageous for therapeutic development. We used a 190 
previously validated all-in-one AAV vector that expresses Nme2Cas9 from the minimal U1a promoter, as 191 
well as a U6 promoter-driven sgRNA targeting Rosa26 (Ibraheim et al. 2018; Edraki et al. 2018) (Fig. 4A). 192 
We also generated AcrIIC3Nme expression plasmids driven by the strong CB-PI promoter and associated 193 
expression elements; in addition, these AcrIIC3Nme constructs either included or omitted the three tandem 194 
miR-122 MREs in the 3’ UTR (Fig. 4A). For in vivo delivery we used hydrodynamic injection, which is a 195 
non-viral method of transient hepatocyte transfection that allows expression from naked DNA plasmids 196 
(Zhang et al. 1999). This injection method delivers DNA to ~20% of hepatocytes for transient expression 197 
and has minimal transgene expression in organs other than the liver. Since miR-122 is abundant in the 198 
liver, and because Cas9 delivered to the liver by hydrodynamic injection can induce editing (Xue et al. 199 
2014), this experimental approach enables tests of liver-specific editing (and inhibition of editing) in the 200 
presence or absence of Acr expression. Plasmids were injected into adult, wild-type C57BL/6 mice via tail 201 
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vein and liver tissues were collected at 7 days post-injection (Fig. 4B). To determine the effective dose of 202 
Acr plasmid needed to inhibit Nme2Cas9 editing in vivo, we co-injected varying Cas9:Acr plasmid ratios 203 
(1:1, 1:1.5, and 1:2). AcrIIC3Nme efficiently inhibited Nme2Cas9 editing at all ratios tested (Fig. 4C). No 204 
apparent liver damage was detected in the liver tissues following staining with haemotoxylin and eosin 205 
(H&E) (Supplemental Fig. 2). Once we defined the necessary plasmid dose, we subjected three groups of 206 
mice to hydrodynamic injection with plasmid combinations that included Nme2Cas9 with (i) no Acr, (ii) 207 
AcrIIC3Nme, and (iii) AcrIIC3Nme-3xmiR122BS (Fig. 4A). In the livers of mice receiving no Acr, Nme2Cas9 208 
yielded a mean editing efficiency of 4.2±0.6% (n = 6 mice), similar to levels seen previously with this and 209 
other Cas9 orthologs upon hydrodynamic injection (Ibraheim et al. 2018; Xue et al. 2014). As expected, 210 
co-injection of AcrIIC3Nme plasmid strongly reduced the editing efficiency to 1±0.5% (P = 0.0025). By 211 
contrast, AcrIIC3Nme-3xmiR122BS failed to inhibit Nme2Cas9 editing, with the indel efficiency 212 
comparable to no Acr group (6.7±1.1%, Fig. 4D). We confirmed the expression of Nme2Cas9 in all three 213 
groups by immunohistochemistry (IHC) against the 3xHA epitope (Supplemental Fig. 3). We were unable 214 
to detect AcrIIC3Nme by IHC against the FLAG epitope in mice injected with AcrIIC3Nme. It is possible that 215 
1xFLAG tag is too weak for IHC detection. However, we ruled out the possibility of injection failures by 216 
including control plasmids in our experiment. Specifically, we co-injected additional plasmids encoding a 217 
Sleeping Beauty transposon system (Ivics et al. 1997) that integrates an mCherry expression cassette into 218 
the mouse genome to report on the success of plasmid injection. In all three groups of injected mice, we 219 
observed mCherry expression in liver tissue sections from injected mice by IHC (Supplemental Fig. 3), 220 
confirming successful liver transfection. In summary, consistent with our results in human Huh-7 cells, 221 
endogenous miR-122 in mouse hepatocytes in vivo can be exploited to repress Acr expression, and 222 
therefore allow tissue-specific Cas9 genome editing, in liver tissues. 223 
 224 
Discussion 225 
 226 
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Although CRISPR-Cas9 technologies have immense promise in numerous aspects of biomedical science, 227 
many applications will benefit from tight temporal or spatial control over Cas9 activity, especially in the 228 
context of clinical development. Confining Cas9 activity to target cells and tissues of interest is highly 229 
desirable to prevent unforeseen adverse effects associated with off-tissue and off-target editing in vivo. 230 
Natural inhibitors of Cas proteins, anti-CRISPRs, can be repurposed as tools to limit the potential for 231 
unwanted edits. Acrs have several potential advantages for implementation as regulators. They are 232 
natural and genetically encodable inhibitors of Cas nucleases that have evolved as powerful inactivators of 233 
CRISPR immunity, usually offering some degree of specificity for particular types of systems. Moreover, 234 
their inhibition is often tunable/titratable based on the relative expression levels of Acrs and the target 235 
effectors, based upon stoichiometric mechanisms of action for most of them (van Gent and Gack 2018; 236 
Bondy-Denomy 2018). Most Acrs are small proteins that can tolerate fusions of fluorescent proteins or 237 
epitope tags, which could make them convenient for in vivo delivery by viral vectors or mRNAs and 238 
detection by fluorescence. 239 
 240 
Here, we present a proof-of-concept demonstration of anti-CRISPR regulation by endogenous miRNAs 241 
in vivo, yielding tissue-specific control over CRISPR-Cas9 editing. We demonstrated that miRNA-242 
mediated inhibition of anti-CRISPRs bearing hepatocyte-specific miR-122 MREs allows genome editing 243 
in a human hepatocyte cell line, Huh-7. Although this study used AcrIIC3Nme for type II-C Nme1Cas9 244 
and Nme2Cas9, as well as AcrIIC4Lmo for SpyCas9, any well-validated combination of Acr-Cas nuclease 245 
will be compatible with this strategy, making it a versatile platform. With the wealth of new Acrs 246 
emerging for different CRISPR effectors (e.g. Cas12a; (Watters et al. 2018; Marino et al. 2018), we expect 247 
that opportunities for implementing this strategy will continue to increase. We also note that expression 248 
profiles of many miRNAs are well-defined for many tissues at many developmental stages and in 249 
numerous disease states (Alvarez-Garcia and Miska 2005). For example, miR-1 is highly and specifically 250 
expressed in cardiac and skeletal muscle tissues (Horak et al. 2016). The miRNA-repressible Acr system 251 
affords great flexibility in changing editing tissue specificity, given the ease with which the MREs can be 252 
.CC-BY-NC-ND 4.0 International licensecertified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (which was notthis version posted May 8, 2019. . https://doi.org/10.1101/631689doi: bioRxiv preprint 
Lee et al., 11 
swapped in the 3’UTR of the Acr transcript. Furthermore, because MREs are so small, this approach is 253 
well suited for viral modes of delivery (given the genome capacity constraints of viral vectors), and could 254 
confer specificity for some tissues that lack vector-compatible, tissue-specific promoters.   255 
 256 
We extend this strategy to animal studies that document anti-CRISPR efficacy during Cas9-mediated 257 
editing in vivo. To our knowledge, this is the first demonstration of in vivo expression of Acr proteins in 258 
vertebrate models to inhibit Cas9 editing activity. From this study, we did not observe overt toxicity in the 259 
transfected liver tissues, although the safety and immunity profiles of delivered Acr proteins will need to 260 
be examined over longer periods of time and in additional biological contexts. 261 
 262 
We exploited endogenous miRNAs for spatial control of anti-CRISPR expression to achieve tissue-263 
specific editing by Cas9 in vivo. The endogenous miRNA repertoire has been combined with the CRISPR-264 
Cas machinery previously to regulate the expression of Cas9 itself (Hirosawa et al. 2017; Senís et al. 2014). 265 
Whereas detargeting Cas9 expression from the liver (e.g. with miR-122) will allow editing to occur 266 
everywhere except the liver, our strategy will restrict Cas9 activity to the liver itself and protect all the 267 
other tissues. This will be particularly useful to restrict Cas9 genome editing to a single desired tissue 268 
following a systemic Cas9 delivery by AAV. Our results complement a strategy described by Wang et al., 269 
which exploits miRNAs to release sgRNAs from longer, inactive precursors (Wang et al. 2019), though 270 
this approach has not yet been validated in tissue-specific editing applications in vivo. While this 271 
manuscript was in preparation, Hoffman et al. also reported using miRNA-regulated Acr proteins to 272 
achieve cell-type specific editing in hepatocytes and myocytes in culture (Hoffmann et al. 2019). Our 273 
studies further demonstrate that miRNA-repressible anti-CRISPRs can be applied in the tissues of adult 274 
mammals in vivo.  275 
  276 
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Materials and Methods 277 
 278 
Vector construction 279 
Codon-optimized AcrIIC3Nme and AcrIIA4Lmo sequences were ordered as gBlocks (IDT) and amplified 280 
using the primers with overhangs to the pCSDest vector by NEBuilder® HiFi DNA Assembly (NEB). 281 
Similarly, an mCherry ORF was fused to the C-terminus of each Acr by HiFi DNA assembly (NEB). To 282 
insert 3xmiR122 MREs in the 3’ UTR of each Acr, top and bottom strands were ordered as oligos (IDT) 283 
with restriction sites for SacI and HindIII and annealed before ligating into the vector linearized with the 284 
same restriction enzymes. For in vivo work, we used the hNme2Cas9-sgRNA_Rosa26 all-in-one AAV 285 
vector (Edraki et al. 2018). To make scAAV vectors expressing Acr proteins, the original scAAV plasmid 286 
encoding an EGFP ORF (a kind gift from J. Xie and G. Gao) and pCSDest-Acr plasmids were digested 287 
with SacI and AgeI restriction enzymes and then ligated. The sequences of codon-optimized Acr 288 
constructs and miRNA-122 MREs are also provided in the Supplemental Table 1. All plasmids used in 289 
this study are summarized in Supplemental Table 2 and will be available on Addgene. 290 
 291 
Cell culture and transfection 292 
HEK293T and Huh-7 cell lines were cultured in Dulbecco’s modified Eagle’s medium supplemented 293 
with 10% fetal bovine serum (Sigma) and 1% penicillin-streptomycin (Gibco). For editing experiments in 294 
vitro, a total of 150 ng of Cas9, 150 ng of sgRNA, and 50 ng of Acr plasmids were transiently transfected 295 
in a 24-well format using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. For 296 
Western blot analysis, 500 ng of each Acr vector and GFP plasmid used as a transfection control were 297 
transfected in a 6-well format using Lipofectamine 2000 (Invitrogen). The total DNA amount was kept 298 
constant by adding a stuffer plasmid in all cases. 299 
 300 
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Flow cytometry 301 
Transfected cells were trypsinized, washed in PBS, and resuspended in PBS for analysis on a 302 
MACSQuant® VYB from Miltenyi Biotec. A yellow laser (561 nm) with a 615/20 nm filter and a blue 303 
laser (488 nm) with a 525/50 nm filter were used for mCherry and GFP detection, respectively. 304 
Subsequent analysis was performed using FlowJo® v10.4.1. Cells were first sorted based on forward and 305 
side scattering (FSC-A vs SSC-A), and then single cells were gated using FSC-A and FSC-H. Finally, 306 
mCherry-positive cells were recorded after gating for GFP-positive (transfected) cells. 307 
 308 
Western blots 309 
Proteins were collected 48 hours post-transfection and their concentrations were measured using the 310 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Western blots were performed as described 311 
previously (Lee et al. 2018) with primary mouse anti-FLAG (AbClonal, 1:5000) used for Acr detection 312 
and rabbit anti-HSP60 (1:5000) used for a loading control. After incubation with secondary anti-Rabbit 313 
or anti-Mouse antibodies (LI-COR IRDye®, 1:20,000), blots were visualized using a LI-COR imaging 314 
system. 315 
 316 
Mouse studies 317 
C57BL/6 mice were obtained from Jackson Laboratory and all animal maintenance and procedures were 318 
performed following the guidelines of the Institutional Animal Care and Use Committee of the University 319 
of Massachusetts Medical School. Plasmids for hydrodynamic tail-vein injection were prepared using the 320 
EndoFreeMaxi kit (Qiagen). For hydrodynamic liver injection, a total of 90 ug of endotoxin-free plasmids 321 
was suspended in 2 ml of injection-grade saline and injected via the tail vein into 8- to 10-week-old 322 
C57BL/6 mice. Mice were euthanized 7 days post-injection and liver tissues were collected and stored at 323 
-80°C for analyses. 324 
 325 
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Indel analysis 326 
Genomic DNA from cells or liver tissues were collected using DNeasy Blood & Tissue Kit (Qiagen). 327 
Target sites were amplified using High Fidelity 2X PCR Master Mix (NEB). Primers used for PCR are 328 
listed in Supplementary Materials. PCR products were purified using DNA Clean & Concentrator Kit 329 
(Zymo) and sent for Sanger sequencing to obtain trace files (Genewiz). Indel values were estimated using 330 
the TIDE web tool (https://tide-calculator.nki.nl/). 331 
 332 
Statistical analysis 333 
Standard deviations are derived from each group that has a minimum of three independent replicates 334 
unless otherwise noted. Unpaired, two-tailed t-test was used to determine the statistical significance 335 
between each group. Resulting P-values < 0.05, 0.01 and 0.001 are indicated by one, two, or three 336 
asterisks, respectively. 337 
 338 
Imunohistochemistry 339 
Liver tissues were fixed in 4% formalin overnight, paraffin-embedded, and sectioned at the UMass 340 
Morphology Core. For Supplemental Figure 2, sectioned slides were stained with H&E for pathology 341 
analysis. For IHC, liver sections were dewaxed, rehydrated, and stained following standard protocols 342 
previously described (Xue et al. 2011) with primary antibodies against 3xHA-tagged Nme2Cas9 (anti-HA; 343 
Cell Signaling) and mCherry (anti-RFP; Rockland). Representative images are shown. 344 
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Figure Legends 365 
 366 
Figure 1. Overview of Cas9 and microRNA-repressible anti-CRISPR system 367 
A. MiRNA-repressible anti-CRISPR and Cas9 editing strategy as designed for use in mice. As an 368 
example, miR-122 can be used to achieve liver-specific editing. Upon systemic delivery of Cas9 in 369 
vivo (e.g. via viral vectors), tissues receiving Cas9 and sgRNA potentially result in genome editing; 370 
however, co-delivery of miRNA-repressible anti-CRISPR proteins will prevent such editing in 371 
non-target tissues that lack miR-122, as depicted in the heart (left). In liver, anti-CRISPR 372 
transcripts with perfectly complementary miR-122 binding sites will undergo Ago2-mediated 373 
mRNA degradation, and the resulting silencing of the Acr will permit Cas9 editing in the liver 374 
(right). 375 
B. A schematic of expression vectors for Cas9 orthologs from type II-A (SpyCas9) and II-C 376 
(Nme1Cas9 and Nme2Cas9) systems, along with their respective anti-CRISPR proteins, 377 
AcrIIA4Lmo and AcrIIC3Nme. The Acr expression constructions were generated with or without 378 
three tandem, perfect complementary miRNA-122 binding sites in the 3’ UTR. CMV, 379 
cytomegalovirus promoter; NLS, nuclear localization signal; AAAA, poly-A tail. 380 
 381 
Figure 2. Validation of miRNA regulation of anti-CRISPR expression in cultured cells 382 
(A, B) Hepatocyte-specific silencing of anti-CRISPR expression. Plasmid vectors shown in Fig. 1B 383 
encoding either AcrIIC3Nme-mCherry or AcrIIA4Lmo-mCherry, with or without miR-122 MREs, 384 
were transfected into (A) human hepatoma (Huh7) cells or (B) non-hepatic HEK293; only the 385 
former express miR-122. The expression of mCherry and GFP was visualized by fluorescence 386 
microscopy (top) and analyzed by flow cytometry (bottom left). The percentage of mCherry-387 
positive cells in each transfection was normalized to transfection of the control GFP-expressing 388 
plasmid. Anti-CRISPR protein expression was also confirmed by western blot against the 389 
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1xFLAG epitope (bottom right). Heat shock protein 60 (HSP60) was used as a loading control. 390 
Scale bar, 400 µm. 391 
 392 
Figure 3. Hepatocyte-specific genome editing by Nme1Cas9, Nme2Cas9 and SpyCas9 in cultured cells 393 
(A-C) HEK293T and Huh7 cells were transiently transfected with plasmids encoding (A) 394 
Nme1Cas9 and an sgRNA targeting the VEGFA locus, (B) Nme2Cas9 and an sgRNA targeting 395 
LINC01588, and (C) SpyCas9 and an sgRNA targeting the BCL11A enhancer. (A, B) AcrIIC3Nme 396 
constructs with or without 3xmiR122BS were co-transfected with the Cas9 and sgRNA constructs 397 
as indicated. (C) AcrIIA4Lmo with or without 3xmiR122BS were co-transfected with SpyCas9 and 398 
its sgRNA. Data represent mean ± s.e.m with at least 3 replicates. Editing efficiencies are 399 
measured by TIDE. 400 
 401 
Figure 4. Acr inhibition of Nme2Cas9 editing in vivo, and release from inhibition by the liver-specific 402 
miRNA, miR-122 403 
A. Plasmids used for in vivo studies to drive the expression of Nme2Cas9/sgRNA and AcrIIC3Nme, 404 
respectively. U1a, murine promoter; BGH, bovine growth hormone polyA signal; CB-PI, 405 
cytomegalovirus-enhancer, chicken β-actin (CB) promoter with SV40-derived mini-intron. 406 
B. A schematic of mouse studies. Plasmid vectors shown in (A) are administered into 8- to 10-week-407 
old C56BL/6 mice by hydrodynamic tail vein injection. Liver tissues were collected one week 408 
after injection. 409 
C. Dose titration of Nme2Cas9/sgRNA plasmid to AcrIIC3Nme plasmid in vivo. Percentage of indels 410 
at the Rosa26 target in the livers of C57Bl/6 mice measured by TIDE after hydrodynamic 411 
injection of Nme2Cas9/sgRNA and AcrIIC3Nme plasmids at mass ratios of 1:1, 1:1.5, and 1:2. 412 
D. Genome editing in the liver by Nme2Cas9 is inhibited by AcrIIC3Nme but restored when 413 
AcrIIC3Nme-3xmiR122BS is silenced. Indel percentages at the Rosa26 locus in the livers of 414 
C57Bl/6 mice was measured by TIDE after hydrodynamic injection of Nme2Cas9/sgRNA 415 
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plasmid, along with anti-CRISPR plasmids with or without 3xmiR122BS. N = 6 mice per group. 416 
ns = not significant, p < 0.01 by unpaired, two-tailed t-test. 417 
 418 
Supplemental Figure Legends 419 
 420 
Supplemental Figure 1. Editing in different organs collected 50 days after rAAV8 delivery of all-in-one 421 
hNme1Cas9/sgRNA targeting Rosa26 via tail vein injection in C56BL/6 mice (n = 3). Indels are 422 
measured by TIDE analysis. Gastr., gastrocnemius muscle. 423 
 424 
Supplemental Figure 2. H&E staining of liver tissue sections from mice injected with hNme2Cas9 and 425 
AcrIIC3Nme expression plasmids at different ratios exhibit no overt toxicity. Scale bar, 100 µm. 426 
 427 
Supplemental Figure 3. Immunohistochemistry of liver tissues from mice injected with 428 
hNme2Cas9/sgRNA plasmid alone, with AcrIIC3Nme plasmid, or with AcrIIC3Nme-3xmiR122BS, as in 429 
Fig. 4D. Anti-mCherry was used to detect mCherry expression from injection control plasmids. Anti-HA 430 
was used for 3xHA tagged hNme2Cas9 detection. Control, saline-injected. Scale bar, 100 µm. 431 
 432 
Supplemental Materials 433 
Table 1. Sequences of codon-optimized anti-CRISPR proteins. 434 
Table 2. Plasmids and oligonucleotides used in this study. 435 
 436 
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Supplemental Table 1. Sequences of codon-optimized anti-CRISPR proteins. 
AcrIIC3Nme 
ATGTTCAAACGGGCCATTATTTTCACCAGCTTCAACGGCTTCGAGAAGGTCAGTCGCACGGAAAAACGGCGCCTT
GCCAAGATAATTAACGCCAGAGTTAGTATAATCGACGAGTATCTTCGCGCCAAAGACACCAACGCCTCCTTGGAC
GGACAGTATAGAGCATTCCTTTTCAATGATGAGTCACCAGCGATGACCGAATTCCTCGCTAAGCTCAAGGCGTTC
GCAGAAAGCTGTACTGGTATAAGCATTGATGCGTGGGAGATTGAAGAGAGCGAGTATGTTCGATTGCCCGTCGAA
CGGAGAGATTTCCTTGCGGCGGCCAATGGCAAAGAAATTTTCAAAATT 
AcrIIA4Lmo 
ATGAACATCAATGATCTGATTAGAGAAATAAAGAATAAAGACTATACTGTTAAATTGTCTGGAACTGACAGTAAT
AGCATAACCCAACTCATCATCAGGGTTAATAATGATGGTAACGAATATGTTATAAGTGAGTCCGAGAACGAATCT
ATCGTCGAGAAGTTCATCAGTGCCTTCAAAAACGGATGGAACCAAGAGTACGAGGATGAGGAGGAATTTTACAAT
GATATGCAAACAATCACTCTGAAGAGCGAGCTTAAC 
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Supplemental Table 2. Plasmids and oligonucleotides used in this study. 
Oligonucleotides used for cloning 3xmiR-122BS  
Top strand AGCTTGACAAACACCATTGTCACACTCCAACAAACACCATTGTCACACTCCAACAAACACCATTGTCACACTCCACCATAGAGCT 
Bottom strand CTATGGTGGAGTGTGACAATGGTGTTTGTTGGAGTGTGACAATGGTGTTTGTTGGAGTGTGACAATGGTGTTTGTCA 
 
Plasmids used in this study Source 
pEJS1146-pCSDest-AcrIIC3Nme-mCherry This study 
pEJS1147-pCSDest-AcrIIC3Nme-mCherry-miR122BS This study 
pEJS1148-pCSDest-AcrIIA4-mCherry This study 
pEJS1149-pCSDest-AcrIIA4-mCherry-miR122BS This study 
pEJS956-AAV.U1a.hNme2Cas9.Rosa26 Addgene #119924 
pEJS804-pscAAV-CB-PI-co.op.AcrIIC3Nme-FLAG/NLS This study 
pEJS828-pscAAV-CB-PI-co.op.AcrIIC3Nme-FLAG/NLS-miR122BS This study 
pEJS789-pscAAV-CB-PI-EGFP Gao lab 
pEJS1173-pLKO.1Spy sgRNA-BCL11A Wolfe lab 
pEJS504-pLKO.1 Nme SgRNA-NTS33 Sontheimer lab 
pEJS1155-pLKO.1-Nme2-sgRNA-DeTS6 Sontheimer lab 
TIDE primers    
Target site Spacer sequence Forward primer Reverse primer 
Nme1Cas9_VEGFA GCGGGGAGAAGGCCAGGGGTCACT GTGTGCAGACGGCAGTCACTAGG CGTTCCCTCTTTGCTAGGAATATTGAAG 
Nme2Cas9_LINC01588 GCCTCCCTGCAGGGCTGCTCCC AGAGGAGCCTTCTGACTGCTGCAGA AGGTCCTGGCCTTGCCTTCGA 
SpyCas9_BCL11A CTAACAGTTGCTTTTATCAC CTCCATCACCAAGAGAGCCTTC TGTGCATAAGTAAGAGCAGATAGC 
Nme2Cas9_Rosa26 CTCCCAGGCCCAGGGCGGTCCTCA TCAGTTGGGCTGTTTTGGAG TAGGGGTTGGATAAGCCAGT 
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